(Q30470922)

21 June 2017

1 reference

title

Psychiatric symptom-provoking studies: an ethical appraisal (English)

1 reference

21 June 2017

0 references

Miller FG

1

1 reference

21 June 2017

Rosenstein DL

series ordinal

2

1 reference

21 June 2017

language of work or name

English

0 references

publication date

1 September 1997

1 reference

21 June 2017

published in

Biological Psychiatry

1 reference

21 June 2017

volume

42

1 reference

21 June 2017

issue

5

1 reference

21 June 2017

page(s)

403-409

1 reference

Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900189-3

Drug-free research in schizophrenia: an overview of the controversy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900189-3

Suicide in psychiatric patients: risk and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900189-3

Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900189-3

L-dopa challenge and relapse in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900189-3

Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900189-3

Comparison of standards for assessing patients' capacities to make treatment decisions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900189-3

Prospective evaluation of panic potentiation following 35% CO2 challenge in nonclinical subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900189-3

Behavioral response to pharmacological challenges: potentials and pitfalls.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900189-3

Methylphenidate increases thought disorder in recent onset schizophrenics, but not in normal controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900189-3

Lactate provocation of panic attacks. I. Clinical and behavioral findings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900189-3

Dysphoria associated with methylphenidate infusion in borderline personality disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900189-3

A laboratory procedure for the induction of flashbacks.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900189-3

Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900189-3

Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900189-3

10.1016/S0006-3223(97)00189-3

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference